DEKK-TEC, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: New Orleans LA United States (1983)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
1999
NCT00002153
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

DEKK-TEC, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

4-demethyl-4-cholesteryloxycarbonylpenclomedine (6 trials)

Drugs in Phase 1 Trials (1)

sivifene (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Neoplasms (Phase 2)

Lymphoproliferative Disorders (Phase 1)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Sarcoma (Phase 1)

Sarcoma, Kaposi (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 2